Biz News Today

Bristol-Myers Squibb Signs New Agreement to Expand Access to Reyataz® (atazanavir sulfate) in sub-Saharan Africa and India

June 28, 2011

Original Source

Investigational Compound Dapagliflozin with Metformin Extended-Release (XR) as Initial Combination Therapy Significantly Improved Blood Sugar Control in Previously-Untreated Adult Type 2 Diabetes Patients with High Blood Sugar Levels

June 27, 2011

Original Source

Investigational Compound Dapagliflozin Added to Metformin Sustained Reductions in Blood Sugar Levels in Adult Patients with Type 2 Diabetes in Two-Year Study

June 26, 2011

Original Source

Investigational Compound Dapagliflozin Sustained Glycemic Control and Weight Reduction in Study of Type 2 Diabetes Patients Inadequately Controlled with Metformin

June 25, 2011

Original Source

Investigational Study Reported ONGLYZA™ (saxagliptin) Added to Insulin Significantly Improved Blood Sugar Levels in Adults with Type 2 Diabetes Compared to Placebo Added to Insulin

June 25, 2011

Original Source

Bristol-Myers Squibb Foundation Awards $1.5 Million in Grants to Help African American Women Fight Type 2 Diabetes

June 24, 2011

Original Source

ELIQUIS® (apixaban) Meets Primary and Key Secondary Endpoints in Phase 3 ARISTOTLE Study

June 22, 2011

Original Source

Bristol-Myers Squibb Announces Dividend

June 22, 2011

Original Source

FDA Approves NULOJIX® (belatacept)

June 16, 2011

Original Source

Bristol-Myers Squibb to Take Part in 2011 Wells Fargo Securities Healthcare Conference

June 16, 2011

Original Source

Bristol-Myers Squibb and Roche Enter into a Clinical Collaboration Agreement to Conduct Combination Studies with YERVOY™ (ipilimumab) and Vemurafenib

June 2, 2011

Original Source

Bristol-Myers Squibb to Take Part in Goldman Sachs Health Care Conference June 8

June 1, 2011

Original Source

Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights

May 23, 2011

Original Source

ELIQUIS® (apixaban) Approved In Europe For Preventing Venous Thromboembolism After Elective Hip Or Knee Replacement

May 20, 2011

Original Source

New Data from Bristol-Myers Squibb Oncology Portfolio to be Presented at 2011 American Society of Clinical Oncology (ASCO) Annual Meeting

May 20, 2011

Original Source

Bristol-Myers Squibb Invites Public to Listen to Webcast of 2011 Annual Meeting

April 29, 2011

Original Source

Bristol-Myers Squibb Delivers Excellent First Quarter with YERVOY™ (ipilimumab) Approval, Key R&D Milestones and Strong Financials

April 28, 2011

Original Source

Bristol-Myers Squibb to Present at Deutsche Bank Health Care Conference

April 26, 2011

Original Source

New Data on Investigational Agent Belatacept in Kidney Transplant Recipients to be Presented at 2011 American Transplant Congress

April 25, 2011

Original Source

Bristol-Myers Squibb to Announce Results for First Quarter 2011 on April 28

April 7, 2011

Original Source

Bristol-Myers Squibb Signs New Agreement to Expand Access to Reyataz® (atazanavir sulfate) in sub-Saharan Africa and India

Investigational Compound Dapagliflozin with Metformin Extended-Release (XR) as Initial Combination Therapy Significantly Improved Blood Sugar Control in Previously-Untreated Adult Type 2 Diabetes Patients with High Blood Sugar Levels

Investigational Compound Dapagliflozin Added to Metformin Sustained Reductions in Blood Sugar Levels in Adult Patients with Type 2 Diabetes in Two-Year Study

Investigational Compound Dapagliflozin Sustained Glycemic Control and Weight Reduction in Study of Type 2 Diabetes Patients Inadequately Controlled with Metformin

Investigational Study Reported ONGLYZA™ (saxagliptin) Added to Insulin Significantly Improved Blood Sugar Levels in Adults with Type 2 Diabetes Compared to Placebo Added to Insulin

Bristol-Myers Squibb Foundation Awards $1.5 Million in Grants to Help African American Women Fight Type 2 Diabetes

ELIQUIS® (apixaban) Meets Primary and Key Secondary Endpoints in Phase 3 ARISTOTLE Study

Bristol-Myers Squibb Announces Dividend

FDA Approves NULOJIX® (belatacept)

Bristol-Myers Squibb to Take Part in 2011 Wells Fargo Securities Healthcare Conference

Bristol-Myers Squibb and Roche Enter into a Clinical Collaboration Agreement to Conduct Combination Studies with YERVOY™ (ipilimumab) and Vemurafenib

Bristol-Myers Squibb to Take Part in Goldman Sachs Health Care Conference June 8

Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights

ELIQUIS® (apixaban) Approved In Europe For Preventing Venous Thromboembolism After Elective Hip Or Knee Replacement

New Data from Bristol-Myers Squibb Oncology Portfolio to be Presented at 2011 American Society of Clinical Oncology (ASCO) Annual Meeting

Bristol-Myers Squibb Invites Public to Listen to Webcast of 2011 Annual Meeting

Bristol-Myers Squibb Delivers Excellent First Quarter with YERVOY™ (ipilimumab) Approval, Key R&D Milestones and Strong Financials

Bristol-Myers Squibb to Present at Deutsche Bank Health Care Conference

New Data on Investigational Agent Belatacept in Kidney Transplant Recipients to be Presented at 2011 American Transplant Congress

Bristol-Myers Squibb to Announce Results for First Quarter 2011 on April 28

Biz News Today Accepts Guest Posts

Recommended Sites